Legal DisputeANIP is currently in a legal dispute regarding the rights to receive a 5% royalty from CGON's cretostimogene sales.
Market RisksRisks include the possibility of generic launches falling short, limited track record for Iluvien/Yutiq, and potential failure to drive Cortrophin volumes.
ValuationThe stock is trading at a valuation more suitable for a pure generics company, despite significant contributions and growth from the rare disease portfolio.